- Head's hundred seals Australia win over England in 1st ODI after Labuschagne strikes
- Dream debut for Wirtz as Leverkusen thump dire Feyenoord
- Myanmar flood death toll climbs to 293: state media
- Israel army says West Bank air strike kills 4 militants
- LIV golfers get green light for US Ryder Cup team, PGA Championship
- US accuses social media giants of 'vast surveillance'
- Ten Hag to bed Hojlund, Mount in carefully when they return for Man Utd
- Breaking bad as McIlroy endures 'weird' day
- EU chief announces $11 bn for nations hit by 'heartbreaking' floods
- Spanish PM, Palestinian leader urge Mideast de-escalation
- New study reinforces theory Covid emerged at Chinese market
- World Bank boosts climate financing by 10 percent
- Bagnaia eyeing summit on home ground in 100th MotoGP
- 'Something was wrong', defendant in French mass rape tells court
- Hezbollah chief admits 'unprecedented' blow in device blasts
- Sales of US existing homes slip slightly in August
- Fear, panic haunt Lebanese after devices explode
- Labuschagne sparks Australia fightback in England ODI opener
- S.Africa's HIV research power couple says fight goes on
- Why is Israel focusing on border with Lebanon?
- Mpox vaccines administered in Rwanda, first in Africa
- US Fed rate cut is 'very positive sign' for economy: Yellen
- Unknown Mozart string trio discovered in Germany
- 'Are we five-year-olds?' F1 drivers won't mind their language
- Brazil judge orders X to reimpose block or face hefty fine
- Munich to rename stadium street after Beckenbauer
- Champions Italy to face Argentina in Davis Cup Final 8
- The winding, fitful path to weight loss drug Ozempic
- Italians defeat American Magic to reach Louis Vuitton Cup final
- Norris has 'nothing to lose' as he hunts Verstappen in Singapore
- Kyiv 'outraged' at Swiss showing of Russian war film
- French city renames Abbe Pierre square after abuse claims
- Footballer charged after huge cannabis seizure at UK airport
- Vatican recognises Medjugorje shrine, but not Virgin's messages
- Israel bombs Hezbollah strongholds in Lebanon after wave of deadly blasts
- Bank of England freezes rate after jumbo US cut
- Playing Nadal is 'kind of a nightmare', says Alcaraz
- Portugal tackles last of deadly northern forest fires
- Ton-up Ashwin lifts India to 339-6 against Bangladesh
- Departing NATO chief warns US against 'isolationism'
- Coming winter 'sternest test yet' for Ukraine energy grid
- Evacuations as tail of Storm Boris floods northeast Italy
- Lebanon's Hezbollah reeling after second wave of deadly blasts
- Taiwan recognises same-sex marriages between Chinese, Taiwanese
- Stock markets rally after jumbo US rate cut
- Gabon's ousted leader Bongo says renouncing politics for good
- Lebanon device blasts: what we know about deadly attacks
- Equity markets rally after jumbo US rate cut
- Late Harrods owner Al-Fayed accused of rape: BBC
- Hong Kong man sentenced 14 months for wearing 'seditious' T-shirt
CMSC | -0.06% | 25.04 | $ | |
BCC | 4.69% | 143.802 | $ | |
JRI | -0.3% | 13.4 | $ | |
RIO | 3.36% | 65.1 | $ | |
BCE | -0.94% | 35.28 | $ | |
GSK | -1.28% | 41.895 | $ | |
SCS | -6.17% | 13.29 | $ | |
RBGPF | 5.79% | 60.5 | $ | |
RYCEF | 5.76% | 6.95 | $ | |
AZN | 0.73% | 79.16 | $ | |
CMSD | 0.16% | 25.02 | $ | |
BTI | -0.7% | 37.615 | $ | |
RELX | 1.69% | 48.185 | $ | |
VOD | -1.49% | 10.08 | $ | |
NGG | -1.6% | 68.95 | $ | |
BP | 1.53% | 32.935 | $ |
New migraine drugs no better than cheap painkillers: big study
New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and even performed worse than an older range of treatments called triptans, said a massive global analysis Thursday.
Migraines are severe, often disabling headaches which affect at least one in seven adults globally, according to the World Health Organization. They are also up to three times more common in women than men.
For decades, cheap and widely available painkillers such as aspirin and ibuprofen have been prescribed for migraines, as well as the more powerful triptans, which change how blood circulates in the brain.
But in recent years, a new generation of migraine drugs called gepants has emerged.
This includes rimegepant, which is sold by US pharma giant Pfizer under the brand name Vydura, and ubrogepant, sold as Ubrelvy by firm Abbvie.
Migraine drugs can represent big money for pharmaceutical firms, as shown when Pfizer acquired Biohaven -- which developed rimegepant -- for more than $10 billion in 2022.
These new drugs have generally been tested against a placebo.
However a new meta-analysis, published in the BMJ journal, brought together 137 previous randomised, controlled trials looking at how 17 different treatments affected a total of nearly 90,000 people.
The newer and more expensive drugs rimegepant and ubrogepant -- as well as another called lasmiditan, which can have drowsy side effects -- were about as effective as paracetamol and anti-inflammatory painkillers, the study said.
Meanwhile triptans -- such as eletriptan, rizatriptan, sumatriptan and zolmitriptan -- performed best, the study said, regretting that they "are currently widely underused".
The researchers recommended doctors first prescribe triptans -- and for certain patients who cannot take triptans due to heart problems, they recommended traditional pain killers such as aspirin and ibuprofen.
The newer gepants drugs should be considered a third option, the study concluded.
Study co-author Andrea Cipriani of Oxford University emphasised how important it was to properly treat the "huge problem" of migraines.
"It's the leading cause of disability in young women and also is associated with high personal health care and societal costs," he told a press conference.
F.Bennett--AMWN